Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is DaVita Stock Underperforming the Nasdaq?
Economy

Is DaVita Stock Underperforming the Nasdaq?

Last updated: September 25, 2025 4:30 am
Share
Is DaVita Stock Underperforming the Nasdaq?
SHARE

DaVita Inc.: An Overview of Market Performance and Future Prospects

Valued with a market capitalization of $9.4 billion, DaVita Inc. (DVA) stands as a key provider of kidney dialysis services catering to patients experiencing chronic kidney failure. Based out of Denver, Colorado, this healthcare entity not only offers various dialysis services, including outpatient, inpatient, and home-based hemodialysis treatments, but also provides clinical laboratory services.

In the financial markets, companies with a valuation of $2 billion or higher are typically categorized as “mid-cap stocks,” and DaVita fits this classification perfectly, boasting a market cap that highlights its significant size, influence, and dominance within the medical care facilities sector. The strength of DaVita lies in its expansive network of dialysis centers situated across the United States, which positions the company to effectively meet the needs of an ever-expanding population of patients diagnosed with chronic kidney disease.

Recent Developments in DaVita’s Market Performance

Despite its strong market presence, DaVita’s stock performance has shown a notable decline. The company has experienced a 27% drop from its 52-week high of $179.60 reached on January 31. Over the past three months, shares of DVA have fallen by 4.2%, significantly underperforming compared to the Nasdaq Composite’s ($NASX) impressive 17.2% gain during the same period.

Furthermore, in the longer-term perspective, DVA’s stock has decreased by 20% over the preceding 52 weeks, an underperformance when contrasted with a 27% increase in the Nasdaq index within the same timeframe. Year-to-date, shares of DVA have declined by 12.3%, whereas the Nasdaq has risen by 18%.

To substantiate its bearish trend, DaVita has been trading below its 200-day moving average since mid-February, with minor fluctuations. Additionally, it has remained under the 50-day moving average since late July.

See also  Dow, S&P 500, Nasdaq move higher with Apple earnings in the wings

www.barchart.com

On August 5, DaVita announced its Q2 results, leading to a steep decline in share prices of more than 9% in subsequent trading. The company reported total revenue growth of 6.1% year-over-year, reaching $3.4 billion, driven by a 4.8% increase in dialysis patient service revenues compared to the same quarter of the previous year. Its adjusted earnings per share (EPS) surged by 47.5% from the prior quarter, reaching $2.95, thanks to significant margin expansion. However, the operating cash flow took a sharp downturn, plummeting 59.4% year-over-year to $324 million, and free cash flow reiterated the trend, falling 76% to $157 million, which heightened investor apprehension.

It is worth noting that DaVita has also lagged behind its primary competitor, Fresenius Medical Care AG (FMS), which has rebounded by 26.7% over the last 52 weeks and enjoyed a 13.5% increase on a year-to-date basis.

Analysts’ Outlook

Considering DaVita’s recent struggles, analysts have adopted a cautious approach regarding its future performance. The stock carries a consensus rating of “Hold” from nine analysts covering it, with a mean price target of $153.57, indicating a potential upside of 17.1% from its current trading levels.


On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data presented here are for informational purposes only. This article was initially published on Barchart.com.

TAGGED:DaVitaNasdaqStockunderperforming
Share This Article
Twitter Email Copy Link Print
Previous Article Brooklyn Beckham Breaks Silence on Family Feud With Parents and Brothers Brooklyn Beckham Breaks Silence on Family Feud With Parents and Brothers
Next Article Rep. Dan Crenshaw Not Buying Jimmy Kimmel's 'New Brand of Gaslighting' Rep. Dan Crenshaw Not Buying Jimmy Kimmel's 'New Brand of Gaslighting'
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Who Got the Biggest Percentage Tax Cuts?

The revelation may catch you off guard. In countless discussions surrounding tax cuts—whether it’s the…

August 6, 2025

Groups That Sued Over Alabama Law Protecting Kids from Trans Agenda Give Up |

In a rather unexpected turn of events, the plaintiffs represented by the American Civil Liberties…

May 4, 2025

Malaikaraiss Berlin Spring 2026 Collection

This season at Malaikaraiss, the spotlight is on cuts and silhouettes that are both comfortable…

July 28, 2025

PM accused of softening language on privatisation

By Giles Dexter of RNZ The Green Party is seeking clarity from the Prime Minister…

January 26, 2025

BlackRock removed from Texas blacklist after climate policy rollback

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favorite…

June 3, 2025

You Might Also Like

Veteran analyst drops sharp take on GTA 6 hype
Economy

Veteran analyst drops sharp take on GTA 6 hype

October 10, 2025
Nvidia’s Jensen Huang Says AI Demand Is Up ‘Substantially’ This Year, and Still Growing
Economy

Nvidia’s Jensen Huang Says AI Demand Is Up ‘Substantially’ This Year, and Still Growing

October 10, 2025
Gold, Silver, and U.S. Stocks Are All at Record Highs. What Gives?
Economy

Gold, Silver, and U.S. Stocks Are All at Record Highs. What Gives?

October 10, 2025
Meme stock resurgence prompts return of central meme investment fund
Economy

Meme stock resurgence prompts return of central meme investment fund

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?